EXEL
Exelixis, Inc.
NASDAQ · USHealthcareBiotechnology
$55.53-0.70%
Price as of Jul 20, 2026
EXEL profitability
Exelixis, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 96.4%
- EBITDA margin
- 42.7%
- EBIT margin
- 39.4%
- Net margin
- 35.1%
- Free cash flow margin
- 38.6%
Returns
- Return on equity
- 43.1%
- Return on assets
- 32.1%
- Return on invested capital
- 44.5%
- Asset turnover
- 0.87x
Cash efficiency
- Cash from operations
- $924.7M
- Cash per share
- $3.09
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.